Figure 9 | Scientific Reports

Figure 9

From: SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)

Figure 9

Proposed mechanism by which ACC inhibition modulates steatosis, TG homeostasis and inflammation. ACC Inhibition is well known to reduce steatosis primarily through inhibition of “de novo lipogenesis". This is also known to be accompanied by elevated SREBP-1c that increases ApoC3 and elevates serum TG. It is possible that compartmental activation of LRP1 could drive the Wnt5a increase and impact lipid homeostasis in liver, while possibly modulating inflammatory endpoints through its activity in macrophages. Increased SREBP-1c activity may also potentiate the modulation of macrophage maturation and expression of CHI3L1. impacting some aspects of systemic inflammation. APOE increase may also potentially contribute to liver steatosis reduction.

Back to article page